argenx (NASDAQ:ARGX) reported that subcutaneous VYVGART Hytrulo met the Phase 3 ALKIVIA primary endpoint, producing a 15.4-point greater mean Total Improvement Score than placebo at Week 52.
Argenx (ARGX) announced the discontinuation of its Phase 3 UplighTED studies for efgartigimod SC in Thyroid Eye Disease (TED) after an interim analysis by an Independent Data Monitoring Committee (IDMC) indicated futility.
Argenx SE (NASDAQ:ARGX) shares are in focus after the U.S. Food and Drug Administration accepted a supplemental Biologics License Application for Vyvgart with Priority Review, potentially expanding the drug's reach to a difficult-to-treat subset of patients with generalized myasthenia gravis (gMG).
argenx (NASDAQ:ARGX) agreed to acquire Forte Biosciences (NASDAQ:FBRX) for $77 per share, valuing the company at $2.2 billion.
Argenx (NASDAQ:ARGX) delivered a powerful start to 2026, reporting first-quarter financial results that demonstrate the accelerating commercial scale of its flagship FcRn blocker, VYVGART.
